Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO DIGIHALER versus ANORO ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO DIGIHALER versus ANORO ELLIPTA.
AIRDUO DIGIHALER vs ANORO ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by increasing cyclic AMP. Fluticasone propionate is a corticosteroid with anti-inflammatory activity that inhibits inflammatory mediators and cells.
ANORO ELLIPTA is a combination of umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Umeclidinium inhibits acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation. Vilanterol stimulates beta2-adrenergic receptors, leading to relaxation of bronchial smooth muscle and increased cyclic AMP.
Two inhalations (umeclidinium 62.5 mcg and vilanterol 25 mcg per inhalation) orally once daily.
One inhalation (umeclidinium 62.5 mcg / vilanterol 25 mcg) once daily, orally inhaled.
None Documented
None Documented
Fluticasone furoate: terminal elimination half-life is approximately 24 hours. Vilanterol: terminal elimination half-life is approximately 11 hours. The long half-life of fluticasone furoate supports once-daily dosing, while vilanterol's half-life allows for sustained bronchodilation over 24 hours.
Umeclidinium: 11 hours (terminal); vilanterol: 2.5 hours (terminal). Steady-state achieved by day 14 once-daily dosing.
Fluticasone furoate and vilanterol are primarily eliminated via biliary/fecal routes. For fluticasone furoate, approximately 90% of an oral dose is excreted in feces as parent drug and metabolites, with <1% in urine. Vilanterol is predominantly excreted via feces (∼70%) as metabolites, with ∼20% in urine.
Umeclidinium: 0.7% unchanged in urine, 58% as metabolites in feces; vilanterol: 26% unchanged in urine, 70% as metabolites in feces. Total elimination: renal (30-40% for vilanterol metabolites) and fecal (primary).
Category C
Category C
Inhaled Corticosteroid/LABA Combination
LAMA/LABA Combination